{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:19:07Z","timestamp":1792487947566,"version":"4.5.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.antiviral.2009.10.003","type":"journal-article","created":{"date-parts":[[2009,10,23]],"date-time":"2009-10-23T08:48:12Z","timestamp":1256287692000},"page":"59-74","source":"Crossref","is-referenced-by-count":301,"title":["Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance"],"prefix":"10.1016","volume":"85","author":[{"given":"Annemarie M.J.","family":"Wensing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje M.","family":"van Maarseveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2009.10.003_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/135965350601100512","article-title":"Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG","volume":"11","author":"Abecasis","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/01.aids.0000188422.95162.b7","article-title":"Protease mutation M89I\/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G","volume":"19","author":"Abecasis","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","article-title":"Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile","volume":"65","author":"Arvieux","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/315726","article-title":"Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine","volume":"182","author":"Atkinson","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","article-title":"Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults","volume":"15","author":"Bartlett","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QAD.0b013e32831c54e5","article-title":"HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review","volume":"23","author":"Bierman","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1468-1293.2005.00327.x","article-title":"Indinavir\/ritonavir 800\/100mg bid and efavirenz 600mg QD in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009","volume":"6","author":"Boyd","year":"2005","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/135965350601100212","article-title":"Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)","volume":"11","author":"Boyd","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1463-1326.2007.00760.x","article-title":"Antiretroviral therapy and the human immunodeficiency virus\u2014improved survival but at what cost?","volume":"10","author":"Bradbury","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.antiviral.2009.10.003_bib10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1086\/508352","article-title":"Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial","volume":"43","author":"Cahn","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib11","first-page":"S18","article-title":"In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir","volume":"12","author":"Callebaut","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00002030-199902040-00009","article-title":"Ritonavir and saquinavir combination therapy for the treatment of HIV infection","volume":"13","author":"Cameron","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib14","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/JCM.39.7.2652-2654.2001","article-title":"Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom","volume":"39","author":"Cane","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00126334-200304010-00005","article-title":"Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects","volume":"32","author":"Cardiello","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir\u2013ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.10.003_bib18","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1185\/030079905X65439","article-title":"Comparison of atazanavir with lopinavir\/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial","volume":"21","author":"Cohen","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.antiviral.2009.10.003_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group","volume":"334","author":"Collier","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib20","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1086\/386291","article-title":"Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens","volume":"189","author":"Colonno","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib21","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1128\/JVI.70.12.8270-8276.1996","article-title":"Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor","volume":"70","author":"Condra","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/00002030-200404300-00024","article-title":"Failure of lopinavir\u2013ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient","volume":"18","author":"Conradie","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0166-3542(91)90045-S","article-title":"Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase","volume":"16","author":"Craig","year":"1991","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2009.10.003_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","article-title":"Atazanavir: a review of its use in the management of HIV-1 infection","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib25","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2165\/00003495-200565120-00005","article-title":"Tipranavir: a ritonavir-boosted protease inhibitor","volume":"65","author":"Croom","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JVI.71.2.1089-1096.1997","article-title":"Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors","volume":"71","author":"Croteau","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib27","doi-asserted-by":"crossref","first-page":"e1000345","DOI":"10.1371\/journal.ppat.1000345","article-title":"Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss","volume":"5","author":"Dam","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2009.10.003_bib28","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1128\/AAC.00149-07","article-title":"In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1","volume":"51","author":"Dandache","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib29","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM199512073332303","article-title":"A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group","volume":"333","author":"Danner","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib30","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.01643-08","article-title":"Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir\u2013ritonavir monotherapy to lopinavir\u2013ritonavir plus zidovudine and lamivudine triple therapy","volume":"53","author":"Delaugerre","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib31","first-page":"S24","article-title":"The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors","volume":"11","author":"De Meyer","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib32","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 3","key":"10.1016\/j.antiviral.2009.10.003_bib33","first-page":"A33","article-title":"Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2","volume":"13","author":"De Meyer","year":"2008","journal-title":"Antivir Ther."},{"issue":"14","key":"10.1016\/j.antiviral.2009.10.003_bib34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/QAD.0b013e32832cbcec","article-title":"Characterization of virologic failure patients on darunavir\/ritonavir in treatment-experienced patients","volume":"23","author":"De Meyer","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/aid.2007.0173","article-title":"Resistance profile of darunavir: combined 24-week results from the POWER trials","volume":"24","author":"De Meyer","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib36","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1096\/fasebj.10.8.8666162","article-title":"Basic concepts in RNA virus evolution","volume":"10","author":"Domingo","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/j.antiviral.2009.10.003_bib37","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/JVI.70.6.3763-3769.1996","article-title":"Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors","volume":"70","author":"Doyon","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2005.07.003","article-title":"Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir","volume":"68","author":"Doyon","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2009.10.003_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1086\/515631","article-title":"Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables","volume":"178","author":"Drusano","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/978-1-4757-9209-6_30","article-title":"In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds","volume":"394","author":"Emini","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/aid.1989.5.577","article-title":"Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease","volume":"5","author":"Erickson-Viitanen","year":"1989","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir\u2013ritonavir versus lopinavir\u2013ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/aid.2006.22.357","article-title":"Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data","volume":"22","author":"Fleury","year":"2006","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib44","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00002030-200205240-00007","article-title":"Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy","volume":"16","author":"Frater","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib45","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/00002030-200409240-00016","article-title":"Isolated lopinavir resistance after virological rebound of a ritonavir\/lopinavir-based regimen","volume":"18","author":"Friend","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/135965350100600206","article-title":"AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients","volume":"6","author":"Gartland","year":"2001","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib47","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1074\/jbc.M108005200","article-title":"Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors","volume":"277","author":"Gatanaga","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.10.003_bib48","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/508353","article-title":"Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial","volume":"43","author":"Gathe","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QAI.0b013e31819c2937","article-title":"A once-daily lopinavir\/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks","volume":"50","author":"Gathe","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/aid.2006.0178","article-title":"Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients","volume":"23","author":"Gathe","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1089\/apc.2006.20.745","article-title":"Successful treatment with atazanavir and lopinavir\/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients","volume":"20","author":"Gilliam","year":"2006","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcv.2005.10.011","article-title":"The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons","volume":"35","author":"Giordano","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib53","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/jac\/dkn099","article-title":"Impact of HIV-1 protease mutations A71V\/T and T74S on M89I\/V-mediated protease inhibitor resistance in subtype G isolates","volume":"61","author":"Gonzalez","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib54","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.48.6.2159-2165.2004","article-title":"Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir","volume":"48","author":"Grossman","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.280.1.35","article-title":"Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up","volume":"280","author":"Gulick","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2009.10.003_bib56","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib57","series-title":"16th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer","author":"Gulnik","year":"2009"},{"key":"10.1016\/j.antiviral.2009.10.003_bib58","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/COH.0b013e328313911d","article-title":"Approaches to the design of HIV protease inhibitors with improved resistance profiles","volume":"3","author":"Gulnik","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib60","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1097\/00002030-199912030-00013","article-title":"A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team","volume":"13","author":"Haubrich","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","article-title":"Durable efficacy of tipranavir\u2013ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib62","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/COH.0b013e3283139134","article-title":"HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models","volume":"3","author":"Hruz","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/331280a0","article-title":"Characterization of ribosomal frameshifting in HIV-1 gag-pol expression","volume":"331","author":"Jacks","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.10.003_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0166-3542(95)00927-2","article-title":"Reduced sensitivity to saquinavir: an update on genotyping from phase I\/II trials","volume":"29","author":"Jacobsen","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2009.10.003_bib65","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.aids.0000166091.39317.99","article-title":"Atazanavir plus ritonavir or saquinavir, and lopinavir\/ritonavir in patients experiencing multiple virological failures","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib66","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.aids.0000216371.76689.63","article-title":"96-Week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virologic failures","volume":"20","author":"Johnson","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.qai.0000242449.67155.1a","article-title":"A once-daily lopinavir\/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen","volume":"43","author":"Johnson","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib68","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1","volume":"16","author":"Johnson","year":"2008","journal-title":"Top. HIV Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib69","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/aid.2008.0310","article-title":"A novel codon insert in protease of clade B HIV type 1","volume":"25","author":"Jordan","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib70","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib72","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib73","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.41.3.654","article-title":"Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir","volume":"41","author":"Kempf","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib74","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1128\/JVI.75.22.11227-11233.2001","article-title":"Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients","volume":"75","author":"Kim","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib75","doi-asserted-by":"crossref","first-page":"12012","DOI":"10.1128\/JVI.78.21.12012-12021.2004","article-title":"Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor","volume":"78","author":"King","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/431197","article-title":"HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors","volume":"41","author":"Kinomoto","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib77","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(95)90699-1","article-title":"Safety and activity of saquinavir in HIV infection","volume":"345","author":"Kitchen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib78","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","article-title":"Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro","volume":"47","author":"Koh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib79","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","author":"Kohl","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib80","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1128\/JVI.02325-07","article-title":"Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region","volume":"82","author":"Koz\u00edsek","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib81","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1073\/pnas.86.3.807","article-title":"Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides","volume":"86","author":"Krausslich","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1468-1293.2003.00143.x","article-title":"Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers","volume":"4","author":"Kurowski","year":"2003","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib83","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1073\/pnas.94.5.1862","article-title":"Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population","volume":"94","author":"Leigh Brown","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nm0397-268","article-title":"HIV-1: gambling on the evolution of drug resistance?","volume":"3","author":"Leigh Brown","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib85","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir\u2013ritonavir compared with that of lopinavir\u2013ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib86","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1128\/JVI.76.15.7398-7406.2002","article-title":"Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro","volume":"76","author":"Maguire","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib87","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","article-title":"Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients","volume":"72","author":"Mammano","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib88","doi-asserted-by":"crossref","first-page":"8524","DOI":"10.1128\/JVI.74.18.8524-8531.2000","article-title":"Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug","volume":"74","author":"Mammano","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/QAI.0b013e318157b0da","article-title":"Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir","volume":"47","author":"Manosuthi","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib90","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1086\/515312","article-title":"A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection","volume":"177","author":"Markowitz","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib91","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection","volume":"333","author":"Markowitz","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib92","first-page":"212","article-title":"Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence","volume":"10","author":"Martinez-Cajas","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2009.10.003_bib93","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1128\/JVI.73.5.3744-3752.1999","article-title":"Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1","volume":"73","author":"Martinez-Picado","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib94","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00007691-200108000-00012","article-title":"Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability","volume":"23","author":"Marzolini","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2009.10.003_bib95","first-page":"175","article-title":"Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy","volume":"2","author":"Mathez","year":"1997","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib96","series-title":"16th Conference on Retroviruses and Opportunistic Infections (CROI)","article-title":"GS-9350: a pharmaco-enhancer without anti-HIV activity","author":"Mathias","year":"2009"},{"key":"10.1016\/j.antiviral.2009.10.003_bib97","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir: a review of its use in the management of HIV infection in adults","volume":"69","author":"McKeage","year":"2009","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.antiviral.2009.10.003_bib98","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"Mills","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib99","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.79.6.3329-3338.2005","article-title":"Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates","volume":"79","author":"Mo","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.10.003_bib101","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib102","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-200312050-00007","article-title":"Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results","volume":"17","author":"Murphy","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/QAD.0b013e3280119213","article-title":"Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients","volume":"21","author":"Naeger","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib104","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/COH.0b013e3283136cee","article-title":"New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors","volume":"3","author":"Nalam","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib105","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/337615a0","article-title":"Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1","volume":"337","author":"Navia","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.10.003_bib106","doi-asserted-by":"crossref","first-page":"14441","DOI":"10.1073\/pnas.95.24.14441","article-title":"Stochastic processes strongly influence HIV-1 evolution during suboptimal protease inhibitor therapy","volume":"95","author":"Nijhuis","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib107","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1097\/00002030-199912030-00006","article-title":"Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy","volume":"13","author":"Nijhuis","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib108","first-page":"S149","article-title":"Substitutions wihin Gag but outside the cleavage sites can cause protease inhibitor resistance","volume":"11","author":"Nijhuis","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib109","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"Nijhuis","year":"2007","journal-title":"PLoS Med."},{"issue":"5","key":"10.1016\/j.antiviral.2009.10.003_bib110","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1086\/605329","article-title":"Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V","volume":"200","author":"Nijhuis","year":"2009","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.antiviral.2009.10.003_bib111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003495-199652010-00007","article-title":"Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection","volume":"52","author":"Noble","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002030-199802000-00006","article-title":"Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir\/3TC\/ZDV Study Group","volume":"12","author":"Notermans","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib113","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"66","author":"Oldfield","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib114","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1128\/JVI.69.9.5228-5235.1995","article-title":"In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease","volume":"69","author":"Partaledis","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib115","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/AAC.40.2.292","article-title":"Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease","volume":"40","author":"Patick","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/dkg392","article-title":"Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects","volume":"52","author":"Paulsen","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib117","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00002030-200207050-00004","article-title":"Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)","volume":"16","author":"Pellegrin","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib118","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/135965350601100407","article-title":"Virological responses to atazanavir\u2013ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)","volume":"11","author":"Pellegrin","year":"2006","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib119","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1086\/515642","article-title":"Relative potency of protease inhibitors in monocytes\/macrophages acutely and chronically infected with human immunodeficiency virus","volume":"178","author":"Perno","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.10.003_bib120","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32825a69a8","article-title":"Virologic efficacy of boosted double versus boosted single protease inhibitor therapy","volume":"21","author":"Petersen","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib121","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.68.12.8017-8027.1994","article-title":"The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions","volume":"68","author":"Pettit","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib122","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir: a review of its use in the management of HIV infection","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib123","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.2165\/00003495-200363120-00007","article-title":"Saquinavir: a review of its use in boosted regimens for treating HIV infection","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2009.10.003_bib124","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1128\/AAC.41.5.1058","article-title":"Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor","volume":"41","author":"Poppe","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2009.10.003_bib126","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00002030-200205030-00007","article-title":"Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity","volume":"16","author":"Prado","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib127","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1310\/MV8B-2YBD-GAM7-PTXX","article-title":"Salvage therapy with ritonavir-boosted amprenavir\/fosamprenavir: virological and immunological response in two years follow-up","volume":"6","author":"Quercia","year":"2005","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2009.10.003_bib128","series-title":"HIV Sequence Compendium 2001","article-title":"HIV-1 fitness: implications for drug resistance, disease progression and global epidemic evolution","author":"Quinones-Mateu","year":"2001"},{"key":"10.1016\/j.antiviral.2009.10.003_bib129","series-title":"49th ICAAC","article-title":"Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir","author":"Ramnathan","year":"2009"},{"key":"10.1016\/j.antiviral.2009.10.003_bib130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.antiviral.2009.10.003_bib131","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.aids.0000226953.56976.ad","article-title":"Atazanavir and lopinavir\/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen","volume":"20","author":"Ribera","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib132","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa074609","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib133","unstructured":"Ritonavir Package Insert. Supplement Number 023. 10-1-2008 (ref type: report)."},{"key":"10.1016\/j.antiviral.2009.10.003_bib134","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/AAC.44.8.2093-2099.2000","article-title":"BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents","volume":"44","author":"Robinson","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00126334-200401010-00003","article-title":"The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients","volume":"35","author":"Rodriguez-French","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib136","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/aid.2007.0276","article-title":"Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring","volume":"24","author":"Rodriguez-Novoa","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2009.10.003_bib137","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/00002030-200110190-00009","article-title":"Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)","volume":"15","author":"Saag","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib138","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/AAC.45.1.30-37.2001","article-title":"Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing","volume":"45","author":"Sadler","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.antiviral.2009.10.003_bib139","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1128\/JVI.00451-09","article-title":"Molecular characterization of clinical isolates of HIV resistant to the protease inhibitor darunavir","volume":"83","author":"Saskova","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib140","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7326\/0003-4819-124-12-199606150-00003","article-title":"The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients","volume":"124","author":"Schapiro","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib141","series-title":"7th European HIV Drug Resistance Workshop, March 25\u201327, 2009","article-title":"Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted mutation score","author":"Scherer","year":"2009"},{"key":"10.1016\/j.antiviral.2009.10.003_bib142","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/00002030-199610090-00010","article-title":"Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)","volume":"10","author":"Schmit","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib143","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1742-6405-5-21","article-title":"Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir\/ritonavir tablet formulation compared with soft gel capsules","volume":"5","author":"Schrader","year":"2008","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib144","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/QAI.0b013e3181a5701c","article-title":"Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir","volume":"51","author":"Sension","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib145","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib146","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1310\/HAG3-8YA5-UDQC-36NX","article-title":"Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients","volume":"6","author":"Smith","year":"2005","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2009.10.003_bib147","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-6405-5-5","article-title":"Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir\/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT","volume":"5","author":"Smith","year":"2008","journal-title":"AIDS Res. Ther."},{"issue":"12","key":"10.1016\/j.antiviral.2009.10.003_bib148","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/QAD.0b013e32832d9031","article-title":"Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor+protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor+nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial","volume":"23","author":"Souli\u00e9","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib149","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0166-3542(95)00916-7","article-title":"In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents","volume":"29","author":"St Clair","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2009.10.003_bib151","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jac\/dkp192","article-title":"A multicentre cohort experience with double-boosted protease inhibitors","volume":"64","author":"Stebbing","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib152","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00002030-199605000-00006","article-title":"A 24-week open-label phase I\/II evaluation of the HIV protease inhibitor MK-639 (indinavir)","volume":"10","author":"Stein","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.10.003_bib153","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class","volume":"41","author":"Turner","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2009.10.003_bib154","series-title":"15th Conference on Retroviruses and Opportunistic Infections","article-title":"Double protease inhibitor, RTI-sparing therapy regimen in naive HIV-1-infected patients: 24-week virologic response analysis of the LORAN trial","author":"Ulbricht","year":"2009"},{"key":"10.1016\/j.antiviral.2009.10.003_bib155","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1073\/pnas.91.9.4096","article-title":"L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor","volume":"91","author":"Vacca","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.10.003_bib156","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/jac\/dkn050","article-title":"Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults","volume":"61","author":"van der Lugt","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib157","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","article-title":"The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes","volume":"41","author":"van de Vijver","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib158","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience","volume":"6","author":"van Heeswijk","year":"2001","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib159","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1468-1293.2002.00123.x","article-title":"First-line ritonavir\/indinavir 100\/800mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results","volume":"3","author":"Voigt","year":"2002","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib160","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/135965350701200803","article-title":"Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients","volume":"12","author":"von Hentig","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.10.003_bib161","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAI.0b013e318198a815","article-title":"Gemini: a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.10.003_bib162","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir\u2013ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.10.003_bib163","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1128\/JVI.72.4.2846-2854.1998","article-title":"Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites","volume":"72","author":"Wiegers","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.10.003_bib164","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.49.7.2575-2582.2005","article-title":"Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms","volume":"49","author":"Winters","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.10.003_bib165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1126\/science.2548279","article-title":"Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease","volume":"245","author":"Wlodawer","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.10.003_bib166","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/JVI.71.9.6662-6670.1997","article-title":"Drug Resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites","volume":"71","author":"Zhang","year":"1997","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209004902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209004902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T08:15:48Z","timestamp":1685175348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354209004902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":166,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0166354209004902"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.10.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}